For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Join our expert, Michael Tackett, Director of Assay Services at Abcam, as he examines real-world case studies to illustrate how multiplex profiling of multi-omic biomarkers can aid in drug discovery and clinical applications.
Published April 28, 2020
Accelerating research while minimizing workloads has been the driving force behind multiplexing laboratory and clinical assays. Incorporating multiplex immunoassays in a multi-omic format brings increased efficiency in the analysis of precious sample resources and can support the successful scale-up of translational research through rapid and reproducible biomarker quantification.
In this webinar, we highlight the successful application of multiplex screening to identify novel potential biofluid-based biomarkers for Parkinson’s Disease in various clinical samples and demonstrate the ability to increase the accuracy of patient stratification for cardiovascular disease using a multi-omic biomarker signature.
Listen below to discover key insights into how multiplexing can accelerate biomarker discovery in disease states and drug screening pipelines.
Michael Tackett did his graduate work in the lab of Andrew Chess at the Massachusetts Institute of Technology, studying the epigenetics of random monoallelic expression in the mouse olfactory system. He then joined the non-profit St. Laurent Institute, where he applied single-molecule sequencing to the study of non-coding RNAs and RNA editing. He then joined Firefly Bioworks and co-developed what is now the FirePlex miRNA assay. He is currently the Director of Assay Services for the FirePlex team at Abcam, leading a team of scientists to bring the benefits of the FirePlex multiplex miRNA and ELISA assays to scientists worldwide through Abcam’s Service Lab.